OpenAI Upgrades GPT-Rosalind with Specialized Biological and Chemistry Reasoning
OpenAI has announced a major update to its specialized GPT-Rosalind model series. GPT-Rosalind is purpose-built for life sciences, drug discovery, and genomics at enterprise scale. Rather than retrieving biology knowledge from a general-purpose language model, GPT-Rosalind is fine-tuned specifically for the multi-step reasoning demands of genomics, medicinal chemistry, and protein engineering.
On June 3, 2026, OpenAI published a substantial update to GPT-Rosalind, deepening its performance and opening the research preview to eligible organizations worldwide for the first time. Along with this update, OpenAI introduced LifeSciBench, a new evaluation framework developed with academic and industry experts to measure end-to-end scientific work across six categories (evidence handling, analysis, design, scientific reasoning, validation, and translation). Three subsidiary benchmarks demonstrate the specialized model's performance improvements:
- GeneBench (Genomics): GPT-Rosalind achieves 21.6% accuracy (vs. GPT-5.5's 20.4%) but completes long-horizon quantitative biology analyses using 31% fewer tokens than GPT-5.5, offering a massive cost reduction for high-throughput genomics pipelines.
- MedChemBench (Medicinal Chemistry): GPT-Rosalind scores 27.5% accuracy (vs. GPT-5.5's 25.1%) while using 7.2% fewer tokens for complex drug design and lead optimization workflows.
- LabWorkBench (Wet-Lab support): Tested on proprietary, uncontaminated laboratory protocols, GPT-Rosalind scores 63.2% accuracy (vs. GPT-5.5's 55.8%) in troubleshooting and reasoning over experimental outcomes.
The updated model runs on top of GPT-5.5's agentic coding and tool-use architecture, integrating with scientific databases and instruments via two new Codex plugins: Life Sciences Research and Life Sciences NGS Analysis. To manage biosecurity risks, OpenAI is keeping access strictly gated under a trusted-access deployment program, which was recently expanded to include pharmaceutical giant Novo Nordisk. Additionally, on May 29, 2026, OpenAI launched the Rosalind Biodefense initiative to extend vetted access to US government agencies and allied partners for pandemic preparedness.